XML 24 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 55 Months Ended 60 Months Ended
Mar. 04, 2020
Nov. 05, 2019
Sep. 06, 2018
Jun. 16, 2015
Feb. 28, 2006
Sep. 30, 2013
Jun. 30, 2006
Jun. 30, 2000
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2019
Mar. 31, 2020
Mar. 31, 2015
Nov. 11, 2011
Revenue from Contract with Customer, Including Assessed Tax                 $ 4,823 $ 5,887            
Arbitration Proceedings of SUL Agreement [Member]                                
Litigation Settlement, Amount Awarded from Other Party $ 5,000,000                              
Arbitration Proceedings of SUL Agreement [Member] | Other Income [Member]                                
Gain (Loss) Related to Litigation Settlement, Total                 6,138              
Arbitration Proceedings of SUL Agreement [Member] | Selling, General and Administrative Expenses [Member]                                
Legal Fees                 4,668              
US Department of Health and Human Services [Member]                                
Collaborative Agreement Contract Value     $ 34,660                          
Contract Term (Year)     5 years                          
Proceeds from Collaborators                       $ 13,864        
US Department of Health and Human Services [Member] | Forecast [Member]                                
Proceeds from Collaborators                     $ 6,932          
Torii Pharmaceutical Co. [Member]                                
Upfront Payments Receivable Amount   $ 22,000                            
Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2020   20,000                            
Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021   $ 15,000                            
Maximum Customary Reduction on Royalty Rate   50.00%                            
Royalty Payments Receivable, Expiration Term From First Commercial (Year)   10 years                            
Revenue from Contract with Customer, Including Assessed Tax                       20,101        
Torii Pharmaceutical Co. [Member] | License [Member]                                
Revenue from Contract with Customer, Including Assessed Tax                       19,344        
Torii Pharmaceutical Co. [Member] | Service [Member]                                
Revenue from Contract with Customer, Including Assessed Tax                       $ 757        
Torii Pharmaceutical Co. [Member] | Minimum [Member]                                
Royalty Rate if Maintains Sakigake Designation   20.00%                            
Royalty Rate, Otherwise   15.00%                            
Torii Pharmaceutical Co. [Member] | Maximum [Member]                                
Royalty Rate if Maintains Sakigake Designation   40.00%                            
Royalty Rate, Otherwise   35.00%                            
CSL Limited [Member                                
Proceeds from License Fees Received       $ 33,740                        
Milestone Payment Received                         $ 12,000      
Royalty Term (Year)       10 years                        
Base Contract [Member]                                
Government Contract Receivable                             $ 16,265  
Additional Development Options [Member]                                
Government Contract Receivable                             22,855  
ASPRBARDA Contract [Member]                                
Government Contract Receivable                             $ 39,120  
Proceeds from awards for Research and Development Contracts                           $ 20,574    
Green Cross Corporation [Member]                                
Proceeds from License Fees Received             $ 250                  
Mundipharma [Member]                                
Upfront Payments Receivable Amount         $ 10,000                      
Potential Milestone Payments Receivable                               $ 15,000
AECOM and IRL [Member]                                
Milestone Payment Minimum               $ 1,400                
Milestone Payment Maximum               4,000                
Annual License Fee Minimum               150                
Annual License Fee Maximum               $ 500                
Advance Notice Period for Termination of Agreement (Day)               60 days                
National Institute of Allergy and Infectious Diseases [Member]                                
Collaborative Agreement Contract Value           $ 5,000                    
Expected Receivable From Awards for Research and Development Contracts                 $ 43,035              
UAB [Member]                                
Period of Agreement (Year)                 25 years              
Renewable Period of Agreement (Year)                 5 years